ThisiscontentfromElsevier'sDrugInformation

    Brincidofovir

    Learn more about Elsevier's Drug Information today! Get the drug data and decision support you need, including TRUE Daily Updates™ including every day including weekends and holidays.

    Feb.07.2024

    Brincidofovir

    Indications/Dosage

    Labeled

    • variola virus (smallpox) infection

    Off-Label

    • monkeypox virus (mpox) infection
    † Off-label indication

    For the treatment of variola virus (smallpox) infection

    Oral dosage (tablets)

    Adults weighing 48 kg or more

    200 mg PO once weekly for 2 doses (on Days 1 and 8).[66710]

    Children and Adolescents weighing 48 kg or more

    200 mg PO once weekly for 2 doses (on Days 1 and 8).[66710]

    Oral dosage (oral suspension)

    Adults weighing 48 kg or more

    200 mg PO once weekly for 2 doses (on Days 1 and 8).[66710]

    Adults weighing less than 48 kg

    4 mg/kg/dose PO once weekly for 2 doses (on Days 1 and 8).[66710]

    Children and Adolescents weighing 48 kg or more

    200 mg PO once weekly for 2 doses (on Days 1 and 8).[66710]

    Children and Adolescents weighing 10 to 47 kg

    4 mg/kg/dose PO once weekly for 2 doses (on Days 1 and 8).[66710]

    Infants and Children weighing less than 10 kg

    6 mg/kg/dose PO once weekly for 2 doses (on Days 1 and 8).[66710]

    Neonates

    6 mg/kg/dose PO once weekly for 2 doses (on Days 1 and 8).[66710]

    For the treatment of monkeypox virus (mpox) infection†

    NOTE: There is no FDA-approved treatment for monkeypox virus (mpox) infections; however, brincidofovir is available for the treatment of monkeypox virus (mpox) infections to clinicians who request and obtain a Single-Patient Emergency Use Investigational New Drug (e-IND). Persons for whom treatment may be considered (after consultation with the FDA) include those with positive test results for monkeypox virus who: [67654]

    • Have severe disease OR are at high risk for progression to severe disease
    • AND meet either of the following:
      • Experience clinically significant disease progression while receiving tecovirimat or who develop recrudescence (initial improvement followed by worsening) of disease after an initial period of improvement on tecovirimat, OR
      • Are otherwise ineligible or have a contraindication for oral or intravenous tecovirimat

    NOTE: Submit single-patient e-IND requests for brincidofovir to the FDA through their emergency IND request for monkeypox treatment. Email (DDI.EIND@fda.hhs.gov) or telephone (301-796-3400 or 855-543-3784) requests may be done during normal business hours. After hours and weekends, call the FDA Emergency Coordinator (866-300-4374 or 301-796-8240) or email CDER-EIND@fda.hhs.gov and call the CDER Emergency Coordinator (301-796-9900).[67654]

    Oral dosage (tablet)

    Adults weighing 48 kg or more

    200 mg PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [68061] [70312] For people with HIV or severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[34362] [70312]

    Adolescents weighing 48 kg or more

    200 mg PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [67802] [68061] [70312] For people with HIV or severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[34362] [70312]

    Children weighing 48 kg or more

    200 mg PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [67802] [68061] [70312] For people with severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[70312]

    Oral dosage (oral suspension)

    Adults weighing 48 kg or more

    200 mg PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [68061] [70312] For people with HIV or severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[34362] [70312]

    Adults weighing less than 48 kg

    4 mg/kg/dose PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [68061] [70312] For people with HIV or severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[34362] [70312]

    Adolescents weighing 48 kg or more

    200 mg PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [67802] [68061] [70312] For people with HIV or severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[34362] [70312]

    Adolescents weighing 10 to 47 kg

    4 mg/kg/dose PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [67802] [68061] [70312] For people with HIV or severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[34362] [70312]

    Children weighing 48 kg or more

    200 mg PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [67802] [68061] [70312] For people with severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[70312]

    Children weighing 10 to 47 kg

    4 mg/kg/dose PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [67802] [68061] [70312] For people with severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[70312]

    Infants and Children weighing less than 10 kg

    6 mg/kg/dose PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [67802] [68061] [70312] For people with severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[70312]

    Neonates

    6 mg/kg/dose PO once weekly for 2 doses (on days 1 and 8); based on individual patient risk-benefit assessment and disease progression, treatment may be extended beyond 14 days, or shortened due to lack of virologic or clinical response or due to adverse events.[66710] [67654] [67802] [68061] [70312] For people with severe immunocompromise and severe disease, consider early intervention with combination therapy at the time of the first medical encounter, in consultation with CDC or an expert in mpox treatment. Additionally, people with HIV not currently taking antiretroviral therapy (ART) should initiate a treatment regimen as soon as possible.[70312]

    Therapeutic Drug Monitoring

    Maximum Dosage Limits

    • Adults

      weighing 48 kg or more: 200 mg/week PO.

      weighing less than 48 kg: 4 mg/kg/week PO.

    • Geriatric

      weighing 48 kg or more: 200 mg/week PO.

      weighing less than 48 kg: 4 mg/kg/week PO.

    • Adolescents

      weighing 48 kg or more: 200 mg/week PO.

      weighing less than 48 kg: 4 mg/kg/week PO.

    • Children

      weighing 48 kg or more: 200 mg/week PO.

      weighing 10 to 47 kg: 4 mg/kg/week PO.

      weighing less than 10 kg: 6 mg/kg/week PO.

    • Infants

      6 mg/kg/week PO.

    • Neonates

      6 mg/kg/week PO.

    Patients with Hepatic Impairment Dosing

    No dosage adjustments are needed.[66710]

    Patients with Renal Impairment Dosing

    No dosage adjustments are needed.[66710]

     

    Hemodialysis

    No dosage adjustments are needed for end-stage renal disease patients on dialysis.[66710]

    † Off-label indication
    Revision Date: 02/07/2024, 12:19:21 PM

    References

    34362 - Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the National Institutes of Health, the Centers for Disease Control and Prevention, the HIV Medicine Association, and the Infectious Diseases Society of America. Accessed Oct 10, 2023. Available at https://clinicalinfo.hiv.gov/en/guidelines/66710 - Tembexa (brincidofovir) package insert. Whippany, NJ: Cambrex Whippany, Inc; 2021 Aug.67654 - Centers for Disease Control and Prevention (CDC). Interim clinical guidance for the treatment of Mpox. July 10, 2023. Retrieved February 7, 2024. Available on the World Wide Web at https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html#anchor_1655488353796.67802 - Centers for Disease Control and Prevention (CDC). Clinical considerations for monkeypox in children and adolescents. September 1, 2023 Retrieved February 7, 2023. Available on the World Wide Web at https://www.cdc.gov/poxvirus/monkeypox/clinicians/pediatric.html?ACSTrackingID=USCDC_1052-DM86528&ACSTrackingLabel=COCA%20Now%3A%20Clinical%20Considerations%20for%20Monkeypox%20in%20Children%20and%20Adolescents&deliveryName=USCDC_1052-DM86528#anchor_1658856112226.68061 - Centers for Disease Control and Prevention (CDC). Expanded Access IND Protocol: Use of tecovirimat (TPOXX) for treatment of human non-variola orthopoxvirus infections in adults and children version 6.3. Updated December 19, 2023. Retrieved February 7, 2024. Available at on the World Wide Web at: https://www.cdc.gov/poxvirus/mpox/clinicians/obtaining-tecovirimat.html.70312 - Rao AK, Schrodt CA, Minhaj FS, et al. Interim clinical treatment considerations for severe manifestations of Mpox - United States, February 2023. MMWR 2023;72:232-43.

    How Supplied

    Brincidofovir Oral suspension

    TEMBEXA 10mg/mL Oral Suspension (79622-0012) (Chimerix, Inc.) null

    Brincidofovir Oral tablet

    TEMBEXA 100mg Tablet (79622-0010) (Chimerix, Inc.) null

    Description/Classification

    Description

    Brincidofovir is an orally administered lipid conjugate of cidofovir, developed to deliver effective intracellular concentrations of the active antiviral metabolite cidofovir diphosphate. It is FDA-approved for the treatment of human smallpox disease due to variola virus. Brincidofovir is also available for expanded access treatment of monkeypox virus (mpox) infections to clinicians who request and obtain a Single-Patient Emergency Use Investigational New Drug (e-IND). To obtain a single-patient e-IND from the FDA, submit requests through their emergency IND request for monkeypox treatment. Email (DDI.EIND@fda.hhs.gov) or telephone (301-796-3400 or 855-543-3784) requests may also be submitted during normal business hours. After hours and on weekends, call the FDA Emergency Coordinator (866-300-4374 or 301-796-8240) or email (CDER-EIND@fda.hhs.gov) and call the CDER Emergency Coordinator at 301-796-9900.[67654] Brincidofovir is indicated for use in adult and pediatric patients and is given once weekly for 2 weeks. DO NOT exceed the recommended dosing regimen, as an increased risk in mortality is possible with prolonged use. Verify a negative pregnancy test in females of reproductive potential before initiating treatment. Advise females of reproductive potential to use effective contraception during treatment and for at least 2 months after the last dose. Men are advised to use condoms during treatment and for at least 4 months after the last dose.[66710]

    Classifications

    • General Anti-infectives Systemic
      • Antivirals For Systemic Use
        • Variola Virus (Smallpox) Antivirals
    Revision Date: 02/07/2024, 12:19:21 PM

    References

    66710 - Tembexa (brincidofovir) package insert. Whippany, NJ: Cambrex Whippany, Inc; 2021 Aug.67654 - Centers for Disease Control and Prevention (CDC). Interim clinical guidance for the treatment of Mpox. July 10, 2023. Retrieved February 7, 2024. Available on the World Wide Web at https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html#anchor_1655488353796.

    Administration Information

    General Administration Information

    For storage information, see the specific product information within the How Supplied section.

    Route-Specific Administration

    Oral Administration

    • Avoid direct contact with tablets that have been broken or crushed or with the oral suspension as brincidofovir is considered a potential carcinogen. If contact with the skin or mucous membranes occurs, wash thoroughly with soap and water, and rinse eyes thoroughly with water.[66710]

    Oral Solid Formulations

    • Administer the tablets on an empty stomach or with a low-fat meal (approximately 400 calories, 25% fat)
    • Swallow each tablet whole. DO NOT crush or divide the tablets.[66710]

    Oral Liquid Formulations

    • Administer the oral suspension on an empty stomach.
    • Shake the suspension before use.
    • Use an appropriate oral dosing syringe to ensure delivery of the prescribed dose.
    • For patients unable to swallow, the oral suspension may be administered via nasogastric or gastrostomy tubes as follows:
      • Draw up the prescribed dose with a calibrated catheter-tip syringe.
      • Administer the dose via the enteral tube.
      • Refill the syringe with 3 mL of water, shake the syringe, and administer the contents of the syringe via the enteral tube.
      • Flush the tube with water before and after enteral administration.
    • Discard any unused portion after completing the 2 prescribed doses.[66710]

    Clinical Pharmaceutics Information

    From Trissel's 2‚Ñ¢ Clinical Pharmaceutics Database
      Revision Date: 02/07/2024, 12:19:21 PM

      References

      66710 - Tembexa (brincidofovir) package insert. Whippany, NJ: Cambrex Whippany, Inc; 2021 Aug.

      Adverse Reactions

      Mild

      • abdominal pain
      • diarrhea
      • dysgeusia
      • maculopapular rash
      • nausea
      • rash
      • vomiting
      • weakness

      Moderate

      • elevated hepatic enzymes
      • hepatitis
      • hyperbilirubinemia
      • peripheral edema

      Gastrointestinal (GI) adverse events experienced by recipients of brincidofovir during the safety clinical trials (n = 392) included diarrhea (8%), nausea (5%), vomiting or retching (4%), and abdominal pain (3%). Diarrhea was a composite term that included irregular bowel movements, defecation urgency, fecal incontinence, and frequent bowel movements. Abdominal pain was a composite term that included abdominal discomfort, distention, pain, and tenderness. All reported GI adverse events started within the first 2 weeks of treatment. Of the 392 patients who received brincidofovir, treatment was stopped in 9 due to diarrhea, 3 due to nausea, 1 due to vomiting, 1 due to enteritis, and 1 due to dyspepsia; all GI adverse events resolved upon treatment discontinuation.[66710]

      Brincidofovir has been associated with elevated hepatic enzymes, increased total bilirubin, and in rare cases (less than 1%) severe hepatobiliary adverse events (e.g., hyperbilirubinemia, acute hepatitis, hepatic steatosis, veno-occlusive hepatic disease). Treatment-emergent liver function test abnormalities reported during the brincidofovir safety clinical trials (n = 392) included Grade 2 and 3 increases in ALT (3% and 2%, respectively), Grade 2 and 3 increases in AST (2% and 1%, respectively), and Grade 2 and 3 increases in total bilirubin (3% and 1%, respectively). Most of the elevations in the liver function tests were reversible and did not require treatment discontinuation; however, 1 patient discontinued treatment due to an ALT greater than 10-times the upper limit of normal. The ALT concentration normalized upon treatment discontinuation. Other treatment-emergent laboratory abnormalities reported during the safety trial included Grade 2 and 3 increases in serum creatinine (4% and less than 1%, respectively).[66710]

      Clinically significant adverse reactions reported in less than 2% of brincidofovir recipients during the safety clinical trials included peripheral edema, decreased appetite, dysgeusia, muscle weakness, and rash (includes generalized rash, maculopapular rash, and pruritic rash).[66710]

      Revision Date: 02/07/2024, 12:19:21 PM

      References

      66710 - Tembexa (brincidofovir) package insert. Whippany, NJ: Cambrex Whippany, Inc; 2021 Aug.

      Contraindications/Precautions

      Absolute contraindications are italicized.

      • breast-feeding
      • contraception requirements
      • dehydration
      • diarrhea
      • hepatotoxicity
      • immunosuppression
      • infertility
      • mortality
      • pregnancy
      • pregnancy testing
      • reproductive risk
      • secondary malignancy

      Based on in vitro data, the conversion of brincidofovir to cidofovir and cidofovir diphosphate (the active moiety) may be reduced in patients with acid sphingomyelinase deficiency; however, the clinical relevance of this finding is unknown.[66710]

      Brincidofovir was associated with an increase in mortality during a Phase 3 clinical trial in which the drug was being evaluating for cytomegalovirus prevention. In this trial, patients were randomized to receive either brincidofovir 100 mg twice weekly or a matching placebo for up to 14 weeks. At Week 24, the all-cause mortality in the brincidofovir group was 16% compared to 10% in the placebo group. Brincidofovir is not indicated for use in any disease other than human smallpox. DO NOT exceed the recommended dosing regimen of 1 dose per week for 2 weeks.[66710]

      Data from immune deficient animals suggest the efficacy of brincidofovir may be reduced in patients with immunosuppression.[66710]

      Perform liver function testing (LFT) on all patients before and during treatment with brincidofovir, as clinically appropriate. Brincidofovir has been associated with hepatotoxicity including elevated hepatic enzymes and severe hepatobiliary adverse events (e.g., hyperbilirubinemia, acute hepatitis, hepatic steatosis, veno-occlusive hepatic disease). Most of the elevations in the LFTs are reversible and do not require treatment discontinuation; however, treatment discontinuation should be considered in patients with ALT concentrations that remain persistently higher than 10-times the upper limit of normal (ULN). DO NOT give the second and final dose on Day 8 if ALT elevations are accompanied by clinical signs of hepatic inflammation or increasing direct bilirubin, alkaline phosphatase, or INR.[66710]

      Monitor brincidofovir treated patients for gastrointestinal (GI) adverse events including diarrhea and dehydration; provide supportive care, and if necessary, do not give the second and final dose on Day 8. During the clinical trials, recipients of brincidofovir experienced diarrhea, nausea, vomiting, and abdominal pain; some of these GI adverse events required treatment discontinuation.[66710]

      It is recommended to use an alternative to brincidofovir, if feasible, for the treatment of smallpox during pregnancy. No human pregnancy data are available to evaluate for a drug-associated risk of major birth defects, miscarriages, or other maternal or fetal outcomes. In animal reproductive studies, brincidofovir administered orally to pregnant rats and rabbits during organogenesis resulted in embryotoxicity, decreased fetal survival, and structural malformations at systemic exposures less than the expected human exposure based on the recommended dose.[66710]

      It is recommended that patients with smallpox avoid breast-feeding, as transmission of the variola virus to the breast-fed infant can occur through direct contact with the mother. There are no data on the presence of brincidofovir in human milk, the effects on the breast-fed infant, or on milk production.[66710]

      Based on data from animals, brincidofovir may be associated with reproductive risk. Verify the pregnancy status in females of reproductive potential with pregnancy testing before initiating treatment with brincidofovir. Discuss contraception requirements with the patients. Advise females of reproductive potential to use effective contraception during treatment and for at least 2 months after the last dose. Men are advised to use condoms during treatment and for at least 4 months after the last dose.[66710]

      Based on testicular toxicity data from animal studies, treatment with brincidofovir may result in irreversible infertility in male drug recipients. In monkeys, twice weekly doses of brincidofovir for 9 months caused atrophy of the seminiferous tubules and hypospermia in the epididymides. After 6 months, these findings showed a trend toward recovery. In rats, twice weekly doses for 13 weeks caused decreased testes weight, depletion of spermatogenesis, and hypospermia. Recovery was not observed in rats after a 12-week post-dosing period. Drug exposures in both the monkeys and rats were less than exposure observed in humans following the recommended 200 mg dose.[66710]

      Avoid direct contact with tablets that are broken or crushed or with the oral suspension as brincidofovir is considered a potential human carcinogen. If contact with the skin or mucous membranes occurs, wash thoroughly with soap and water, and rinse eyes thoroughly with water. In animal studies, secondary malignancy (i.e., mammary adenocarcinomas and squamous cell carcinomas) was observed in rats with systemic exposures less than the expected human exposure based on the recommended dose.[66710]

      Revision Date: 02/07/2024, 12:19:21 PM

      References

      66710 - Tembexa (brincidofovir) package insert. Whippany, NJ: Cambrex Whippany, Inc; 2021 Aug.

      Mechanism of Action

      Brincidofovir is an orthopoxvirus nucleotide analog DNA polymerase inhibitor indicated for the treatment of human smallpox disease caused by the variola virus. The drug is a lipid conjugate of cidofovir, an acyclic nucleotide analog of deoxycytidine monophosphate, that was created to increase intracellular delivery of cidofovir. The lipid conjugate mimics lysophosphatidylcholine (a natural lipid) to use the endogenous lipid uptake pathways. Once inside cells, the lipid ester linkage of brincidofovir is cleaved to release cidofovir, which is then phosphorylated to produce the active moiety, cidofovir diphosphate. Cidofovir diphosphate blocks viral replication by selectively inhibiting orthopoxvirus DNA polymerase-mediated synthesis of viral DNA.

       

      Data from cell cultures show the median 50% effective concentration (EC50) of brincidofovir against variola virus to be 0.11 micromolar (range: 0.05 to 0.21 micromolar) across 5 viral strains. The median EC50 against rabbitpox, ectromelia, vaccinia, and monkeypox viruses were 1.1 micromolar (0.5 to 1.89 micromolar), 0.33 micromolar (0.12 to 0.51 micromolar), 0.17 micromolar (0.004 to 1.2 micromolar), and 0.074 micromolar (0.023 to 0.12 micromolar), respectively. There are no known examples of naturally occurring brincidofovir resistant orthopoxviruses; however, brincidofovir treatment-emergent resistance may develop under drug selection. Certain amino acid substitutions in the target viral DNA polymerase protein can confer reductions in brincidofovir antiviral activity. Cross-resistance with tecovirimat is not expected.[66710]

      Revision Date: 02/07/2024, 12:19:21 PM

      References

      66710 - Tembexa (brincidofovir) package insert. Whippany, NJ: Cambrex Whippany, Inc; 2021 Aug.

      Pharmacokinetics

      Brincidofovir is administered orally. Once in systemic circulation, the drug is more than 99.9% bound to human plasma proteins and has a volume of distribution of 1,230 L; the blood-to-plasma ratio is between 0.48 and 0.61. Brincidofovir is a prodrug that is hydrolyzed intracellularly by acid sphingomyelinase to cidofovir, which is then phosphorylated to cidofovir diphosphate (the active moiety). Brincidofovir is also metabolized by CYP4F2 to form the inactive metabolites CMX103 (3-hydroxyproply ester of cidofovir) and CMX064 (4-(3-propoxy)butanoic acid ester of cidofovir). Radiolabeled doses of brincidofovir showed excretion of the metabolites occurred through the urine (51%) and feces (40%). The apparent clearance is 44.1 L/hour and the mean terminal half-life is 19.3 hours.[66710]

       

      Affected cytochrome P450 isoenzymes and transporters: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP4F2, BCRP, MRP2, BSEP, OATP1B1, OAT1, OAT3

      In vitro studies show brincidofovir inhibits CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP4F2. The drug also inhibits the following transporters: breast cancer resistance protein (BCRP), multidrug resistance-associated protein 2 (MRP2), bile salt export pump (BSEP), organic anion transporting polypeptides 1B1 (OATP1B1), and organic anion transporters 1 and 3 (OAT1 and OAT3). Brincidofovir is a substrate for CYP4F2. Further, data from a drug interaction study suggests brincidofovir is also a substrate for OATP1B1 and OATP1B3, as administration with an OATP1B1/3 inhibitor increased the mean exposure and maximum plasma concentration of brincidofovir by 374% and 269%, respectively.[66710]

      Route-Specific Pharmacokinetics

      Oral Route

      The oral bioavailability of the brincidofovir tablet and suspension are 13.4% and 16.8%, respectively. Under fasted conditions, the time to reach maximum plasma concentration (Tmax) is 3 hours (range: 2 to 8 hours). Administration of the tablet formulation with a low-fat meal (i.e., 400 calories, 25% fat) decreases brincidofovir exposure (AUC) and maximum plasma concentration (Cmax) by 31% and 49%, respectively; however, there are no clinically relevant changes in the intracellular cidofovir diphosphate concentration. The effects of food on the pharmacokinetics of the oral suspension have not been evaluated. In healthy adults, administration of a single dose resulted in a brincidofovir AUC of 3,400 ng x hour/mL and Cmax of 480 ng/mL; the AUC and Cmax of cidofovir diphosphate was 1,200 pg x hour/106 cells and 9.7 pg/106 cells.[66710]

      Special Populations

      Hepatic Impairment

      No clinically relevant differences in the pharmacokinetics of brincidofovir have been observed based on hepatic function.[66710]

      Renal Impairment

      No clinically relevant differences in the pharmacokinetics of brincidofovir have been observed based on renal function, including patients with end-stage renal disease not on dialysis. Exposures (AUC) and maximum plasma concentrations (Cmax) of brincidofovir and cidofovir are comparable in patients requiring hemodialysis whether on- or off-dialysis.[66710]

      Pediatrics

      No clinically relevant differences in the pharmacokinetics of brincidofovir have been observed based on age. Doses of the oral suspension are predicted to provide pediatric patients, including neonates, with exposures comparable to those observed in adults who receive the oral tablets.[66710]

      Geriatric

      No clinically relevant differences in the pharmacokinetics of brincidofovir have been observed based on age.[66710]

      Gender Differences

      No clinically relevant differences in the pharmacokinetics of brincidofovir have been observed based on gender.[66710]

      Ethnic Differences

      No clinically relevant differences in the pharmacokinetics of brincidofovir have been observed based on ethnicity.[66710]

      Revision Date: 02/07/2024, 12:19:21 PM

      References

      66710 - Tembexa (brincidofovir) package insert. Whippany, NJ: Cambrex Whippany, Inc; 2021 Aug.

      Pregnancy/Breast-feeding

      pregnancy

      It is recommended to use an alternative to brincidofovir, if feasible, for the treatment of smallpox during pregnancy. No human pregnancy data are available to evaluate for a drug-associated risk of major birth defects, miscarriages, or other maternal or fetal outcomes. In animal reproductive studies, brincidofovir administered orally to pregnant rats and rabbits during organogenesis resulted in embryotoxicity, decreased fetal survival, and structural malformations at systemic exposures less than the expected human exposure based on the recommended dose.[66710]

      breast-feeding

      It is recommended that patients with smallpox avoid breast-feeding, as transmission of the variola virus to the breast-fed infant can occur through direct contact with the mother. There are no data on the presence of brincidofovir in human milk, the effects on the breast-fed infant, or on milk production.[66710]

      Revision Date: 02/07/2024, 12:19:21 PM

      References

      66710 - Tembexa (brincidofovir) package insert. Whippany, NJ: Cambrex Whippany, Inc; 2021 Aug.

      Interactions

      Level 1 (Severe)

      • Cidofovir

      Level 3 (Moderate)

      • Amoxicillin; Clarithromycin; Omeprazole
      • Asciminib
      • Atazanavir
      • Atazanavir; Cobicistat
      • Clarithromycin
      • Cobicistat
      • Cyclosporine
      • Darolutamide
      • Darunavir; Cobicistat
      • Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide
      • Elexacaftor; tezacaftor; ivacaftor
      • Eltrombopag
      • Eluxadoline
      • Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Alafenamide
      • Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Disoproxil Fumarate
      • Enasidenib
      • Encorafenib
      • Erythromycin
      • Fostemsavir
      • Gemfibrozil
      • Glecaprevir; Pibrentasvir
      • Isoniazid, INH; Pyrazinamide, PZA; Rifampin
      • Isoniazid, INH; Rifampin
      • Lansoprazole; Amoxicillin; Clarithromycin
      • Leflunomide
      • Leniolisib
      • Letermovir
      • Lopinavir; Ritonavir
      • Midostaurin
      • Nirmatrelvir; Ritonavir
      • Pretomanid
      • Rifampin
      • Smallpox Vaccine, Vaccinia Vaccine
      • Sofosbuvir; Velpatasvir
      • Sofosbuvir; Velpatasvir; Voxilaprevir
      • Teriflunomide
      • Trofinetide
      • Voclosporin
      • Vonoprazan; Amoxicillin; Clarithromycin
      Amoxicillin; Clarithromycin; Omeprazole: (Moderate) Postpone the administration of clarithromycin for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and clarithromycin is necessary. Brincidofovir is an OATP1B1/3 substrate and clarithromycin is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [56579] [66710] Asciminib: (Moderate) Postpone the administration of asciminib for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and asciminib is necessary. Brincidofovir is an OATP1B1/3 substrate and asciminib is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [66710] [67087] Atazanavir: (Moderate) Postpone the administration of atazanavir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and atazanavir is necessary. Brincidofovir is an OATP1B1 substrate and atazanavir is an OATP1B1 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1 inhibitor. [61511] [61512] [66710] Atazanavir; Cobicistat: (Moderate) Postpone the administration of atazanavir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and atazanavir is necessary. Brincidofovir is an OATP1B1 substrate and atazanavir is an OATP1B1 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1 inhibitor. [61511] [61512] [66710] (Moderate) Postpone the administration of cobicistat for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and cobicistat is necessary. Brincidofovir is an OATP1B1/3 substrate and cobicistat is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [58000] [66710] Cidofovir: (Contraindicated) Do not administer brincidofovir with intravenous cidofovir as use of these drugs together is considered duplicate therapy. Brincidofovir is a lipid-linked derivative of cidofovir that is intracellularly converted to cidofovir. [66710] Clarithromycin: (Moderate) Postpone the administration of clarithromycin for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and clarithromycin is necessary. Brincidofovir is an OATP1B1/3 substrate and clarithromycin is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [56579] [66710] Cobicistat: (Moderate) Postpone the administration of cobicistat for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and cobicistat is necessary. Brincidofovir is an OATP1B1/3 substrate and cobicistat is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [58000] [66710] Cyclosporine: (Moderate) Postpone the administration of cyclosporine for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and cyclosporine is necessary. Brincidofovir is an OATP1B1 substrate and cyclosporine is an OATP1B1 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with a single 600 mg oral cyclosporine dose. [56579] [66710] Daclatasvir: (Moderate) Postpone the administration of daclatasvir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and daclatasvir is necessary. Brincidofovir is an OATP1B1/3 substrate and daclatasvir is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [60001] [66710] Darolutamide: (Moderate) Postpone the administration of darolutamide for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and darolutamide is necessary. Brincidofovir is an OATP1B1/3 substrate and darolutamide is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [64525] [66710] Darunavir; Cobicistat: (Moderate) Postpone the administration of cobicistat for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and cobicistat is necessary. Brincidofovir is an OATP1B1/3 substrate and cobicistat is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [58000] [66710] Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: (Moderate) Postpone the administration of cobicistat for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and cobicistat is necessary. Brincidofovir is an OATP1B1/3 substrate and cobicistat is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [58000] [66710] Elexacaftor; tezacaftor; ivacaftor: (Moderate) Postpone the administration of elexacaftor for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and elexacaftor is necessary. Brincidofovir is an OATP1B1/3 substrate and elexacaftor is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [64697] [66710] Eltrombopag: (Moderate) Postpone the administration of eltrombopag for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and eltrombopag is necessary. Brincidofovir is an OATP1B1 substrate and eltrombopag is an OATP1B1 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1 inhibitor. [40392] [66710] Eluxadoline: (Moderate) Postpone the administration of eluxadoline for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and eluxadoline is necessary. Brincidofovir is an OATP1B1 substrate and eluxadoline is an OATP1B1 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1 inhibitor. [59741] [66710] Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Alafenamide: (Moderate) Postpone the administration of cobicistat for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and cobicistat is necessary. Brincidofovir is an OATP1B1/3 substrate and cobicistat is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [58000] [66710] Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Disoproxil Fumarate: (Moderate) Postpone the administration of cobicistat for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and cobicistat is necessary. Brincidofovir is an OATP1B1/3 substrate and cobicistat is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [58000] [66710] Enasidenib: (Moderate) Postpone the administration of enasidenib for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and enasidenib is necessary. Brincidofovir is an OATP1B1/3 substrate and enasidenib is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [62181] [66710] Encorafenib: (Moderate) Postpone the administration of encorafenib for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and encorafenib is necessary. Brincidofovir is an OATP1B1/3 substrate and encorafenib is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [63317] [66710] Erythromycin: (Moderate) Postpone the administration of erythromycin for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and erythromycin is necessary. Brincidofovir is an OATP1B1/3 substrate and erythromycin is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [56579] [66710] Fostemsavir: (Moderate) Postpone the administration of fostemsavir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and fostemsavir is necessary. Brincidofovir is an OATP1B1/3 substrate and fostemsavir is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [65666] [66710] Gemfibrozil: (Moderate) Postpone the administration of gemfibrozil for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and gemfibrozil is necessary. Brincidofovir is an OATP1B1 substrate and gemfibrozil is an OATP1B1 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1 inhibitor. [41940] [66710] Glecaprevir; Pibrentasvir: (Moderate) Postpone the administration of glecaprevir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and glecaprevir is necessary. Brincidofovir is an OATP1B1/3 substrate and glecaprevir is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [62201] [66710] (Moderate) Postpone the administration of pibrentasvir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and pibrentasvir is necessary. Brincidofovir is an OATP1B1/3 substrate and pibrentasvir is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [62201] [66710] Isoniazid, INH; Pyrazinamide, PZA; Rifampin: (Moderate) Postpone the administration of rifampin for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and rifampin is necessary. Brincidofovir is an OATP1B1/3 substrate and rifampin is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [56579] [66710] Isoniazid, INH; Rifampin: (Moderate) Postpone the administration of rifampin for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and rifampin is necessary. Brincidofovir is an OATP1B1/3 substrate and rifampin is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [56579] [66710] Lansoprazole; Amoxicillin; Clarithromycin: (Moderate) Postpone the administration of clarithromycin for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and clarithromycin is necessary. Brincidofovir is an OATP1B1/3 substrate and clarithromycin is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [56579] [66710] Leflunomide: (Moderate) Postpone the administration of leflunomide for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and leflunomide is necessary. Brincidofovir is an OATP1B1/3 substrate and leflunomide is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [49634] [66710] Leniolisib: (Moderate) Postpone the administration of leniolisib for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and leniolisib is necessary. Brincidofovir is an OATP1B1/3 substrate and leniolisib is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [66710] [68778] Letermovir: (Moderate) Postpone the administration of letermovir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and letermovir is necessary. Brincidofovir is an OATP1B1/3 substrate and letermovir is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [62611] [66710] Lopinavir; Ritonavir: (Moderate) Postpone the administration of lopinavir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and lopinavir is necessary. Brincidofovir is an OATP1B1 substrate and lopinavir is an OATP1B1 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1 inhibitor. [61510] [61511] [61513] [66710] Midostaurin: (Moderate) Postpone the administration of midostaurin for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and midostaurin is necessary. Brincidofovir is an OATP1B1 substrate and midostaurin is an OATP1B1 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1 inhibitor. [61906] [66710] Nirmatrelvir; Ritonavir: (Moderate) Postpone the administration of ritonavir-boosted nirmatrelvir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and ritonavir-boosted nirmatrelvir is necessary. [65314] [66710] Pretomanid: (Moderate) Postpone the administration of pretomanid for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and pretomanid is necessary. Brincidofovir is an OATP1B3 substrate and pretomanid is an OATP1B3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B3 inhibitor. [64561] [66710] Rifampin: (Moderate) Postpone the administration of rifampin for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and rifampin is necessary. Brincidofovir is an OATP1B1/3 substrate and rifampin is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [56579] [66710] Smallpox Vaccine, Vaccinia Vaccine: (Moderate) Animal data suggest that coadministration of brincidofovir at the same time as the live smallpox vaccine may reduce the immune response to the vaccine. However, the clinical impact of this potential interaction on vaccine efficacy is unknown. [66710] Sofosbuvir; Velpatasvir: (Moderate) Postpone the administration of velpatasvir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and velpatasvir is necessary. Brincidofovir is an OATP1B1/3 substrate and velpatasvir is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [60911] [66710] Sofosbuvir; Velpatasvir; Voxilaprevir: (Moderate) Postpone the administration of velpatasvir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and velpatasvir is necessary. Brincidofovir is an OATP1B1/3 substrate and velpatasvir is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [60911] [66710] (Moderate) Postpone the administration of voxilaprevir for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and voxilaprevir is necessary. Brincidofovir is an OATP1B1/3 substrate and voxilaprevir is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [62131] [66710] Teriflunomide: (Moderate) Postpone the administration of teriflunomide for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and teriflunomide is necessary. Brincidofovir is an OATP1B1/3 substrate and teriflunomide is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [51794] [66710] Trofinetide: (Moderate) Postpone the administration of trofinetide for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and trofinetide is necessary. Brincidofovir is an OATP1B1/3 substrate and trofinetide is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [66710] [68701] Voclosporin: (Moderate) Postpone the administration of voclosporin for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and voclosporin is necessary. Brincidofovir is an OATP1B1 substrate and voclosporin is an OATP1B1 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1 inhibitor. [66336] [66710] Vonoprazan; Amoxicillin; Clarithromycin: (Moderate) Postpone the administration of clarithromycin for at least three hours after brincidofovir administration and increase monitoring for brincidofovir-related adverse reactions (i.e., elevated hepatic enzymes and bilirubin, diarrhea, other gastrointestinal adverse events) if concomitant use of brincidofovir and clarithromycin is necessary. Brincidofovir is an OATP1B1/3 substrate and clarithromycin is an OATP1B1/3 inhibitor. In a drug interaction study, the mean AUC and Cmax of brincidofovir increased by 374% and 269%, respectively, when administered with another OATP1B1/3 inhibitor. [56579] [66710]
      Revision Date: 02/07/2024, 12:19:21 PM

      References

      40392 - Promacta (eltrombopag) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023 Mar.41940 - Lopid (gemfibrozil) package insert. New York, NY: Pfizer Inc.; 2017 April.49634 - Arava (leflunomide) package insert. Bridgewater, NJ:. Sanofi-Aventis U.S. LLC; 2016 Feb.51794 - Aubagio (teriflunomide) tablets package insert. Genzyme Corporation: Cambridge, MA; 2021 Apr.56579 - Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Updated Mar 10, 2020. Retrieved from the World Wide Web at www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm58000 - Tybost (cobicistat) package insert. Foster City, CA: Gilead Sciences, Inc; 2021 Sept.59741 - Viberzi (eluxadoline) package insert. Parsippany, NJ: Actavis Pharma, Inc.; 2020 June.60001 - Daklinza (daclatasvir) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2019 Oct.60911 - Epclusa (sofosbuvir; velpatasvir) tablet and oral pellets package insert. Foster City, CA: Gilead Sciences, Inc; 2022 Apr.61510 - Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570-57861511 - Karlgren M, Ahlin G, Bergstrom CA, et al. In Vitro and In Silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res. 2012;29:411-42661512 - Busti AJ, Bain AM, Hall RG, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastin. J Cardiovasc Pharmacol. 2008;51:605-61061513 - Annaert P, Ye ZW, Stieger B, et al. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010;40(3):163-17661906 - Rydapt (midostaurin) capsule package insert. East Hanover,NJ: Novartis Pharmaceuticals Corporation; 2023 May.62131 - Vosevi (sofosbuvir; velpatasvir; voxilaprevir) tablet package insert. Foster City, CA: Gilead Sciences, Inc; 2019 Nov.62181 - Idhifa (enasidenib) tablet package insert. Summit, NJ: Celgene Corporation; 2023 Dec.62201 - Mavyret (glecaprevir; pibrentasvir) tablets package insert. North Chicago, IL: AbbVie Inc.; 2023 Oct.62611 - Prevymis (letermovir) package insert. Rahway, NJ: Merck Sharp and Dohme, LLC.; 2023 Aug.63317 - Braftovi (encorafenib) capsules package insert. Boulder, CO: Array BioPharma Inc.; 2023 Oct.64525 - Nubeqa (darolutamide) tablets package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2023 Oct.64561 - Pretomanid tablet package insert. Hyderabad, India: Mylan, Laboratories Limited; 2022 Dec.64697 - Trikafta (elexacaftor; tezacaftor; ivacaftor and ivacaftor tablets) package insert. Boston, MA; Vertex Pharmaceuticals Incorporated: 2023 August.65314 - COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Accessed March 1, 2024. Available at https://www.covid19treatmentguidelines.nih.gov/65666 - Rukobia (fostemsavir) package insert. Durham, NC: ViiV Healthcare; 2024 Feb.66336 - Lupkynis (voclosporin) capsules package insert. Rockville, MD: Aurinia Pharma U.S., Inc.; 2021 Jan.66710 - Tembexa (brincidofovir) package insert. Whippany, NJ: Cambrex Whippany, Inc; 2021 Aug.67087 - Scemblix (asciminib) tablets package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation: 2023 Nov.68701 - Daybue (trofinetide) oral solution package insert. San Diego, CA: Acadia Pharmaceuticals, Inc.; 2023 Mar.68778 - Joenja (leniolisib) package insert. Saint Quentin Fallavier, France; Skyepharma Production SAS. 2023 Mar.

      Monitoring Parameters

      • LFTs
      • pregnancy testing

      US Drug Names

      • Tembexa
      Small Elsevier Logo

      Cookies are used by this site. To decline or learn more, visit our cookie notice.


      Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

      Small Elsevier Logo
      RELX Group